Search

Background: Toxic Epidermal Necrolysis (TEN), also known as Lyell's syndrome, is a rare but severe connective tissue condition that is a common cause of substantial skin damage as well as mucous membrane breakdown. This condition is distinguished by the detachment of the epidermis presenting as blisters and denuded skin areas along with erythema. Supportive care is typically the mainstay in the primary treatment of TEN. The effectiveness of systemic steroids remains uncertain due to the limited availability of studies that directly compare the utility of these therapeutic approaches. Here, we report a case where TEN was successfully treated with dexamethasone. Case Presentation: We present a case of an 18-year-old female patient who presented with complaints of itchy skin lesions, multiple purpuras and petechiae following ingestion of a dose of a cefadroxil tablet. A diagnosis of cefadroxil-induced Toxic Epidermal Necrolysis was made. Hydration therapy along with systemic steroids and topical treatments were administered to the patient. The lesions healed gradually and the condition of the patient improved. [ABSTRACT FROM AUTHOR]

Background: Postpartum Depression (PPD) is one of the least vocalized topics surrounding pregnancy and motherhood in India. The study aimed to assess the postpartum depression in women who had cesarean and normal vaginal deliveries. Materials and Methods: In this study, we identify postpartum depression in recently postpartum women and compare it in different maternal ages, modes of delivery (cesarean and vaginal), and sexes of the babies, since very few studies have explored these as risk factors. Data were obtained over six months from 210 women via their responses to the Edinburgh Postnatal Depression Scale (EPDS). An EPDS score of =7 out of 30 was set to determine postpartum depression, which was further classified as mild, moderate, or severe. Results: Total of 210 patients analyzed in the study out of which 157 (74.7%) exhibited PPD, which was more common in mothers aged between 19 and 27 years, and those who delivered via cesarean section. Mild depression was the most frequently occurring severity overall. Conclusion: Screening of PPD and providing suitable education should be encouraged during postpartum care or child-care visits for identifying and managing PPD, which in turn improves child development. [ABSTRACT FROM AUTHOR]

Background: The drug Finerenone, a selective the drug mineralocorticoid receptor antagonist, indicated for Chronic Kidney Disease (CKD) and Type 2 Diabetes. Recent researchers also found add on role in the management of resistant hypertension. So, this review article aims to provide an in-depth understanding of finerenone and the objective is to explore the mechanism of action, efficacy, and potential benefits of finerenone in treating (CKD) and heart failure with reduced ejection fraction (HFrEF), specifically in patients who have both type 2 diabetes (T2D) and CKD. Materials and Methods: A systematic literature search was done using IBM Micromedex, PubMed, Cochrane Library, and Scopus databases to identify relevant English-language articles published between 2000 and March 2023. Search terms included "Finerenone," "MRA," "Resistant Hypertension," "Finerenone Efficacy," and "Pharmacology of Finerenone." The selection criteria included clinical trials, randomized trials, and original articles, with references listed chronologically. Results: Finerenone's selective blockade of mineralocorticoid receptors counteracts the adverse effects of aldosterone, exhibiting anti-inflammatory and anti-fibrotic properties. Clinical trials consistently demonstrate its efficacy in reducing albuminuria, slowing CKD progression, and improving cardiovascular outcomes in patients with T2D and CKD. The recent approval of finerenone by the FDA for reducing the risk of death and abnormal cardiovascular events in adults with CKD and T2D with HFrEF highlights its therapeutic potential. Conclusion: Finerenone represents a pharmacological breakthrough in the management of resistant hypertension, offering a comprehensive therapeutic approach for patients with CKD and T2D. Its selective mineralocorticoid receptor antagonism, combined with anti-inflammatory and anti-fibrotic effects, shows promise in improving long-term renal and cardiovascular health. However, further research is needed to fully understand its long-term benefits, safety profile, and optimal utilization in the management of resistant hypertension. Finerenone's emergence provides new possibilities for patient care and signifies a significant advancement in the treatment of CKD and T2D, with the potential to enhance patient outcomes and quality of life. [ABSTRACT FROM AUTHOR]